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Abstract A compound exhibits tautomerism if it can
be represented by two structures that are related by an
intramolecular movement of hydrogen from one atom to
another. The different tautomers of a molecule usually
have different molecular ﬁngerprints, hydrophobicities and
pKa’s as well as different 3D shape and electrostatic
properties; additionally, proteins frequently preferentially
bind a tautomer that is present in low abundance in water.
As a result, the proper treatment of molecules that can
tautomerize, *25% of a database, is a challenge for every
aspect of computer-aided molecular design. Library design
that focuses on molecular similarity or diversity might
inadvertently include similar molecules that happen to be
encoded as different tautomers. Physical property mea-
surements might not establish the properties of individual
tautomers with the result that algorithms based on these
measurements may be less accurate for molecules that can
tautomerize—this problem inﬂuences the accuracy of ﬁl-
tering for library design and also traditional QSAR. Any
2D or 3D QSAR analysis must involve the decision of if or
how to adjust the observed Ki or IC50 for the tautomer-
ization equilibria. QSARs and recursive partitioning
methods also involve the decision as to which tautomer(s)
to use to calculate the molecular descriptors. Docking
virtual screening must involve the decision as to which
tautomers to include in the docking and how to account for
tautomerization in the scoring. All of these decisions are
more difﬁcult because there is no extensive database of
measured tautomeric ratios in both water and non-aqueous
solvents and there is no consensus as to the best compu-
tational method to calculate tautomeric ratios in different
environments.
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Introduction
Molecules that can exist as different tautomers are cha-
meleons. By virtue of a proton hopping from one polar
atom to another and the rearrangement of double bonds or
ring opening or closing, a particular atom changes from a
hydrogen-bond donor to an acceptor while another atom in
the molecule changes from a hydrogen-bond acceptor to a
hydrogen-bond donor. Tautomeric reactions in which a
heterocyclic ring is opened and closed also change the
shape of the molecule.
Small changes in molecular structure or solvent envi-
ronment can dramatically change the ratio of tautomers:
Such changes complicate the assignment of a physical
property measurement to a speciﬁc chemical structure, the
identiﬁcation of the bioactive species from a tautomeric
mixture, and the probability that a ‘‘minor’’ species is the
one recognized by a macromolecule.
Although there are many reasons for not carefully con-
sidering tautomers in computer assisted drug design, the
time has come to take up the challenge. This perspective is
not a comprehensive review, but rather a sampling of the
experimental information available on tautomers, the
implications of these observations, and possible approaches
to a more reliable consideration of tautomers in drug
design. Although others have also highlighted the issue of
tautomers [1–6], the full impact of tautomerism has not
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Experimental observations of tautomers
Rate of tautomerization
In general, if the tautomerism involves moving a proton
from one heteroatom to another, the reaction is fast, par-
ticularly in aqueous solutions [7]. In these cases, NMR
studies see both tautomers [8] and experimental measure-
ments of log P, log D,o rp Ka contain contributions from
all tautomers unless the analytical detection method has
been speciﬁcally designed to detect only one. On the other
hand, tautomerization may be slow if it involves a ring-
chain equilibrium or if it involves moving a proton from a
heteroatom to carbon atom.
Examples of the relationship between structure,
solvent, and the tautomer ratio
The ratio of tautomers of any compound is highly depen-
dent on the structure of the solute well as the solvent [7, 9].
For example, crystallization conditions may induce dif-
ferent tautomers of the same molecule or the two forms
might co-exist in a single crystal [10–13].
Figure 1 shows examples of tautomeric equilibria in
water [9]. Note that the equilibrium between 4-hydroxy-
pyridine and 4-pyridone is affected by the solvent, by
intramolecular hydrogen bonding, and by the electronic
effects of substituents. In water the thione form of
4-mercaptopyridine predominates, but the equilibrium
switches to the thiol form for 2-mercaptothiophene. The
absence of numbers for some of the equilibrium constants
in Fig. 1 indicates that although it was possible to establish
the predominant tautomer, it was not possible to quantitate
the concentration of the minor form.
Figure 2 shows an example of the change in tautomer
ratio as a function of solvent and of structure [14]. The
replacement of one of a pair of enolizable hydrogens by a
methyl group increases the proportion of the NH form in all
solvents and increases the proportion of the OH form in
both non-polar solvents. Note that tautomerization would
also racemize the chiral carbon of Structure 2.04.
Ring-chain tautomerism is well established in carbohy-
drates, but it also occurs in other molecules such as war-
farin, Fig. 3 [15]. An example of the substituent effect on
this type of equilibrium is shown in Fig. 4 [16]. Substitu-
tion of an ortho hydrogen with a nitro group favors the
open form, whereas substitution with an amino or hydroxy
group favors the cyclic form. The equilibrium constant for
ring closure follows a Hammett relationship.
Clearly if one were comparing the biological properties
of the compounds in Figs. 1, 2, 3 and 4, it would be
important to be alert to the possibility that tautomerism
might complicate the structure-activity relationships.
Examples of ligand tautomer preferences
of macromolecules
Often the resolution of a protein crystal structure cannot
clearly establish the tautomer of the bound ligand. How-
ever, there are several documented cases where the bound
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123tautomer has been unambiguously established. Figure 5
illustrates the contrast between the solution structure of a
barbiturate analogue and that in a 1.8 A ˚ crystal structure as
bound to matrix metalloproteinase 8 [17]. Others have
shown with SCRF-HF/6-31G** calculations that the tau-
tomer of unsubstituted barbituric acid that corresponds to
the bound tautomer is 20.05 kcal/mol less stable in polar
medium [18]. Figure 6 shows the tautomer of pterin bound
O
N O
H3C
O
NH O
H3C
O
N HO
H3C
H
Chloroform 40% 60% 19-24%
Dioxane 37-39% 53-59% 4-9%
Water 0% 0% 100%
O
N O
H
O
NH O O
N HO
H
Chloroform 100% 0% 0%
Dioxane 90-100% 0-3% 0-7%
Water 70% 0% 30%
H H
2.01 2.02 2.03
2.04 2.05 2.06
Fig. 2 The effect of changes in
structure and solvent on
tautomeric equilibria of simple
heterocycles [14]
O O
OH O
O O
O O
H
O OH
O O
O O
O O
H
O O
O
HO
O O
O
HO
O O
O
OH
O O
O
OH
3.03 3.02
3.07
3.04 3.06
3.08
3.05
3.01
Fig. 3 The tautomers of
warfarin [15]
J Comput Aided Mol Des (2009) 23:693–704 695
123to the 2.3 A ˚ structure of ricin toxin A-chain. It is 3 kcal/mol
higher in energy (AMSOL in AM1-SM2 Hamiltonians) in
solution than the favored tautomer [19].
In some cases more than one tautomer is bound to the
protein. For example, Fig. 7 shows the two tautomers that
are bound with equal occupancy in a 1.53 A ˚ structure of
CDK [20]. This result contrasts with crystal structures of
similar compounds in KDR [21] and PDGF [22], two other
kinases, in which only the 2,4-dihydroindeno tautomer, the
left structure, is observed. Macrophage migration inhibi-
tory factor (MIF) catalyzes phenylpyruvate tautomeriza-
tion, Fig. 8 [23]. It catalyzes the reaction in both directions,
and hence binds both tautomers, although the enol-keto
direction is preferred.
Enzymes can also select one species from a ring-chain
equilibrium. For example, Fig. 9 shows the tautomers of
chlorthalidone, a carbonic anhydrase inhibitor. The crystal
structure of the carbonic anhydrase II-chlorthalidone
complex shows that it is not bound as the amide form, but
rather as an unusual lactim tautomer [24].
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Fig. 8 Two tautomers recognized by macrophage inhibitory factor
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123Proteins can bind different tautomers of related com-
pounds. For example, glucose is a substrate for xylose
isomerase and xylitol is an inhibitor, Fig. 10. Interestingly,
the 0.95 A ˚ crystal structures show that glucose is bound as
a ring tautomer, not the chain form as expected from the
structure of xylitol [25, 26].
A slightly more complex process is involved with the
anti-tuberculosis drug isoniazid. It ﬁrst forms an adduct
with NAD(P); this adduct then inhibits a long-chain enoyl-
acyl carrier protein reductase (InhA) [27]. Figure 11 sum-
marizes the structures involved. Measurements on model
compounds show that in contrast to the bound structure, in
water the ring tautomer is favored by a factor of 2 [28, 29].
Complementary hydrogen bonds of bases in DNA lead
to the formation of the characteristic double helix of DNA.
When the base-pair mimics shown in Fig. 12 form a double
helix with complementary DNA, the analogue that posi-
tions the tautomerizable group in the major groove is in the
keto-amino tautomer [30]. However, the analogue that
binds in the minor groove is in the syn-enol tautomer. The
differences in tautomer preferences reﬂect the differences
in the character of the major and minor grooves.
Frequency of molecules that can tautomerize
A summary of one program’s enumeration of tautomers
[31] of marketed drugs [32] is shown in Fig. 13. Of the
1,791 compounds, 1,334 or 74% exist as only one tauto-
mer—put another way, 26% exist as an average of three
tautomers. For this dataset and enumeration program 2,949
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123tautomers are found; this increases the size of the dataset
by 1.64-fold. Using a different tautomer generating pro-
gram, others have found similar or slightly more increases
in the size of a database [3]. Hence, although consider-
ation of tautomers will increase the number of structures
considered for virtual screening, the increase should be
manageable.
Calculated properties of tautomers
pKa Differences between tautomers
Because the tautomers of a molecule have different struc-
tures, they differ in their ability to gain or lose a proton;
their pKa values. In the simple case of an ionizable mol-
ecule that has two tautomeric forms, the tautomeric ratio is
a function of the pKa’s of the tautomers. For example,
consider the tautomeric and ionic equilibria of 6-chloro-2-
pyridone in water, Fig. 14. Algebraically Kt = Ka
OX/Ka
OH.
Hence, one can calculate the value of any one of these
equilibrium constants from values of the other two.
The observed pKa of a tautomerizable molecules is a
composite of several individual microscopic ionization
constants and the tautomeric equilibrium constant(s) [33].
Forexample,theprotonatedformtetracycline(Structure 10)
can be present as any one of nine tautomers, and the neutral
formbyten[34].Eachofthese19speciescouldcontributeto
the observed pKa as well as the biological properties and
octanol-water log D of the molecule. Similarly, 8-oxogua-
nine(Structure 11)canexistasoneormoreof100neutralor
anionic tautomers. This complicates investigations into its
mechanism of mutagenicity [33].
Calculation of the tautomer ratio in solution
Although many workers have investigated the relative
stabilities of tautomers in different liquid phases, because
of the difﬁculty of measuring the equilibrium constants
there is no publically available comprehensive database of
this data. This lack hinders the development of empirical
methods to predict the ratios of tautomers of a molecule.
The implications of the lack of experimental data are
described in detail in an article on predicting pKa[ 35], a
less complex equilibrium constant.
If the tautomerization involves only the movement of a
proton between sites, the tautomer equilibrium constant can
be calculated from the pKa of each tautomer. This rela-
tionship holds because deprotonation of the tautomers lead
to resonance structures of a common structure. Hammett-
type [9] or empirical charge [36] relationships can be used
to calculate the pKa’s of the tautomers and hence the
tautomeric ratio. However, even these calculations have
errors in the range of 0.8 log units [35].
More elaborate, but not necessarily more accurate, cal-
culations involve free-energy perturbation [37] or quantum
chemical calculations [18, 19, 28, 33, 38–48]. To date there
appears to be no consensus as to the most appropriate
method.
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123Calculated octanol-water log P of tautomers
Usually the tautomers of a molecule have different hy-
drophobicities. Because small changes in structure or sol-
vent can dramatically change the tautomeric ratio, ignoring
the possibility of tautomerism leads to complications in
assigning the speciﬁc molecular structure of a substance for
which octanol-water log P has been measured. Indeed,
usually the tautomer ratio in each phase has not been
established. This ambiguity in turn results in inaccuracies
of computational models to predict log P. For example we
[49] and others [50] showed empirically that programs that
calculate octanol-water log P are less accurate for mole-
cules that can tautomerize.
Calculated log P values are often used to ﬁlter com-
pounds for virtual screening, presumably because of its
inverse correlation with water solubility [51–53] or per-
meability [52]. Such relationships have not been investi-
gated to see if they also apply to molecules that can
tautomerize.
In addition, calculated log P values might be used to
predict brain to blood ratio using the simple equation that
includes terms for log P and polar surface area, PSA [54].
Although PSA is quite similar for tautomers, the ﬁgures
in this report show that tautomers of a molecule usually
have different hydrophobicities. The question then
becomes, which log P value should be used in the brain
penetration calculation—should we assume that blood is
like water and use the log P of the dominant form in
water, or do we recognize that tautomerization is fast and
use the log P of the more hydrophobic form to simulate
brain tissue?
Figures 5, 6, 7 and 8 contain values of octanol-water
log P calculated by two popular programs. Note that not
only do the values calculated from the different programs
seldom agree, but often they do not even agree as to which
tautomer is more hydrophobic. As another example,
Table 1 lists the calculated octanol-water log P of the
tautomers of sildenaﬁl (Viagra) and phenobarbital.
Although the programs suggest little difference between
Tautomers 1 and 3 of sildenaﬁl, KowWin predicts that the
enol form, Tautomer 2, is the least hydrophobic, whereas
CLOGP and ALOGP suggest that it is the most hydro-
phobic of the three. As a consequence, CLOGP and
ALOGP predict that Tautomer 2 is the predominant form in
the water-saturated octanol phase, whereas KowWin pre-
dicts that it is the minor form in this phase. Similar
contradictions are seen with the calculated log P of phe-
nobarbital tautomers: CLOGP predicts that Tautomer 1, the
tautomer most highly populated in water, is also the most
hydrophobic tautomer, whereas ALOGP predicts that it is
the least hydrophobic tautomer.
Cheminformatics issues with tautomers
Identifying if a molecule is in a database
This problem has been discussed by others [3, 55, 56].
Because the tautomers of a molecule do not have the same
molecularstructure,they willusually beencoded differently
in the bitmaps or ﬁngerprints that are used to discover if a
particular moleculeisin a database.An example of different
tautomers registered in different databases is seen with sil-
denaﬁl:AlthoughTautomer3(Table 1)hasbeenreportedto
be more stable than Tautomer 1 and it is the one associated
withaChemicalAbstracts[57]Number,Tautomer 1islisted
as the structure in PubChem [58] and ChemSpider [59].
The usual solution to this problem is to use a special
algorithm to generate a unique tautomer, usually one
assumed to predominate in water [3, 55]. Unfortunately,
different software vendors use slightly different algorithms
with the result that the same compound can be represented
differently in different databases.
Substructure searching and identiﬁcation
Substructure search queries that will identify tautomers
need to be constructed with this possibility in mind. For
example, if one uses Structure 1.03 as a search query, if the
ring is speciﬁed to be aromatic, then molecules that contain
Substructure 1.04, perhaps as the N-methyl derivative,
would not be found.
Many cheminformatic investigations involve an analysis
of the substructures present in the molecules under con-
sideration. For example, QSARs or recursive partitioning
may be based on the relative frequency of certain sub-
structures in active versus inactive compounds: Clearly,
such investigations are compromised if they do not include
the substructures that are present in any (or most abun-
dant?) tautomer of the molecule. The examples in Figs. 5,
6, 7, 8, 9, 10, 11 and 12 show that one cannot focus
exclusively on the ‘‘major’’ tautomer.
Similarity searching
Table 2 shows Tanimoto similarities calculated with
ECFP4 ﬁngerprints [31] and the probability, based on the
similarity, that the two compounds will have potency
within 10-fold of each other [60]. The columns on the left
list the similarities and probabilities between tautomers; the
columns to the right list these values for the most similar
molecule in this small dataset. Note that in most cases the
most similar molecule is not a tautomer of the query
molecule. Only if the query structure is rather complex is
the tautomer similar. Note the low similarity between
J Comput Aided Mol Des (2009) 23:693–704 699
123Table 1 Calculations of octanol-water log P of different tautomers of viagra and phenobarbital
Compound Tautomer Structure Octanol-water log P Program
CLOGP [74] KowWin [75] ALOGP [31]
Viagra 1
N
N
O
N
N
H
O
S
O
O N
N
2.22 2.30 2.25
Viagra 2
N
N
OH
N
N
O
S
O
O N
N
3.56 1.60 3.06
Viagra 3
N
N
O
HN
N
O
S
O
O N
N
1.98 2.47 2.25
Phenobarbital 1
HN
O
O O
NH
1.36 1.33 1.32
Phenobarbital 2
N
OH
O O
NH
0.67 0.26 2.00
Phenobarbital 3
HN
O
OH O
N
0.67 0.93 2.00
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Compound Tautomer Structure Octanol-water log P Program
CLOGP [74] KowWin [75] ALOGP [31]
Phenobarbital 4
N
OH
O HO
N
0.67 1.27 2.68
Phenobarbital 5
N
O
OH HO
N
0.67 1.27 2.68
Table 2 Tanimoto similarity
comparisons of structures
(ECFP_4 Fingerprints [31])
a The most similar structure
is a tautomer
Structure Tautomer Most similar structure
Tautomer Similarity Probability of
equal potency (%)
Structure Similarity Probability of
equal potency (%)
101 102 0.07 0.14 103 0.43 18.66
103 104 0.07 0.14 105 0.43 18.66
105 106 0.07 0.14 103 0.43 18.66
107 108 0.06 0.12 105 0.19 0.89
107 109 0.06 0.12 105 0.19 0.89
108 109 0.06 0.12 106 0.23 1.62
110 111 0.04 0.09 104 0.22 1.40
112 113 0.15 0.49 111 0.33 6.57
201 202 0.30 4.42 204 0.33 6.57
203 201 0.26 2.52 206 0.33 6.57
202 203 0.22 1.40 205 0.35 8.42
204 205 0.27 2.91 201 0.33 6.57
204 206 0.25 2.18 205
a 0.27 2.91
205 206 0.25 2.18 202 0.35 8.42
401 405 0.15 0.49 404 0.43 18.66
402 406 0.21 1.20 404 0.49 26.65
403 407 0.23 1.62 404 0.55 25.46
404 408 0.23 1.62 403 0.55 32.07
501 502 0.42 17.23 502
a 0.42 17.23
601 602 0.34 7.45 602
a 0.34 7.45
701 702 0.56 32.70 702
a 0.56 32.70
801 802 0.38 11.81 802
a 0.38 11.81
901 902 0.26 2.52 902
a 0.26 2.52
901 903 0.27 2.91 903
a 0.27 2.91
902 803 0.47 24.20 903
a 0.47 24.20
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123Structures 5.01 and 5.02. This result shows that even
simple similarity searching can be misleading if one
ignores tautomerization.
Because similarity calculations form the basis for clus-
tering and diversity selection, incorrect handling of tau-
tomers can result in erratic results.
Tautomer enumeration programs
Cheminformatics software vendors recognize the problems
that tautomers cause. As a result, most supply a tautomer
enumeration program, generally only heterocyclic tau-
tomers. To date, there has been no comparison of the dif-
ferent programs, probably because there is no recognized
database. The users interested in using a database for vir-
tual screening must then decide if they will enumerate all
possible tautomers or just a few that are likely to be the
most abundant in water.
Implications of tautomerization for QSAR
Figures 1, 2 and 3 remind us that within a series the ratio of
tautomers in either the water or a non-aqueous phase is not
constant. Because QSARs correlate the total concentration
of a molecule with some biological effect, tautomerization
has the effect of adding equilibria in addition to those for
drug-target and drug-distribution. For example, correcting
the observed concentration to that of ‘‘bioactive’’ tautomer
in the aqueous phase does not account for the differential
partitioning of tautomers of the various analogues to inert
nonaqueous and receptor phases or that the target bio-
molecule may recognize a minor tautomer.
As noted above, for substructure-based QSARs, the ﬁrst
issue is to decide which tautomers should be included in
the analysis. The second issue is how the algorithm allows
the model to ignore some of the tautomers of a molecule.
Tautomerization complicates the calculation of molec-
ular descriptors for traditional 2D QSAR [61]. For exam-
ple, it may be ambiguous which calculated log P values to
use as a molecular descriptor. Hence, the reliability of
QSAR analyses that use hydrophobicity as a descriptor
may suffer. In addition, because tautomers of a molecule
have different pKa’s, assigning a physical property to a
speciﬁc molecular structure is especially challenging if the
molecule can also ionize at pHs of interest [62]. On the
other hand for 3D-QSARs, one must decide which tauto-
mer as well as which conformer to use for the analysis.
Implications of tautomerization for docking molecules
High throughput docking programs are generally imprecise
enough that one can attempt to dock all reasonable
tautomers of a molecule. If the objective of the study is to
identify compounds for experimental testing, if any tauto-
mer of a molecule has a high score, validation is provided
by experimental testing.
On the other hand, if the objective of the docking is to
propose the structure of the protein-ligand complex, the
preliminary docked structures would then be reﬁned to
optimize the ﬁt and provide a prediction of afﬁnity. This
optimization would involve exploring the conformation of
the ligand and the protein active site as well as the pro-
tonation and tautomeric state of both.
One strategy is to optimize and calculate the energy of
every possible tautomeric and protonation state of the
system, both in water and in the active site. This can be
done with molecular mechanics force-ﬁelds [6, 19, 63, 64],
with quantum mechanics [25, 29, 64–66], or a combination
of the two [67]. At the current time, no method is partic-
ularly accurate—errors of 0.7–1.0 log units for each of the
components are not uncommon [35, 67–69]. A quantum
mechanical or QM/MM structure optimization would
reveal the bound tautomer of both the ligand and the pro-
tein [67, 70]. For such calculations one would have to
decide the level of theory necessary and whether the whole
complex will be treated quantum mechanically or, if not,
how the boundary between the quantum and molecular
mechanics will be handled. Because a thermodynamic
cycle is involved, the use of any method requires that it can
reliably predict the ratio of tautomers in aqueous systems.
Directions for the future
The need for more experimental data
This review emphasizes the need for more experimental
information on the tautomeric ratio of diverse molecules in
water and various solvents. Such observations would form
the basis for methods to predict the tautomeric ratio and a
test bed to compare the accuracy of the various empirical
and quantum chemical methods. Unfortunately, these
measurements are difﬁcult to design and often require
synthesis of model compounds in hopes that they accu-
rately mimic the properties of the corresponding tautomer.
Careful measurement of the impact of tautomerization
on pKa and water solubility would provide information that
would improve the predictions of these properties.
The need for cheminformatic databases
that can maintain information about tautomers
Once a body of information is available, it might be dis-
covered that enhancements must be made to the current
architecture for storing chemical structures and information
702 J Comput Aided Mol Des (2009) 23:693–704
123[56]. For example, consider the problem of a database that
would store all of the tautomers of Structures 10 or 11.
Such a database would need to store not only the canonical
tautomer but also structures and available properties of
each individual tautomer, the measured or calculated
equilibrium constants between the tautomers, and the
properties of the compound itself.
The need for computer programs that predict
ring-chain tautomerization
Rules for ring formation in organic synthesis have been
formulated by Baldwin [71]. These would provide a start-
ing point for a program that would enumerate ring-chain
tautomers, a capability absent from the current tautomer
generation programs.
The need for validation of the various
computational methods
Although the various methods to explore the structure and
energetics of enzyme-ligand complexes are interesting, for
such methods to be useful they must be validated. For
example is the continuum solvent assumption sufﬁcient, or
is it important to include explicit water molecules in the
calculation? Before QM/MM calculations can be used in
routine investigations of protein-ligand complexes, they
will need to run faster and with less human interaction. A
point to be examined would be whether a semi-empirical
method [72, 73] might be sufﬁcient for the quantum
mechanical portion of the calculation and, indeed, whether
the whole system can be accurately calculated with semi-
empirical methods.
Summary
Tautomerization equilibria present a continuing challenge
to computer-aided molecular design, affecting everything
from library design to SAR to docking and scoring protein-
ligand interactions. The absence of experimental data and
validated computational methods make tautomerization
easy to ignore but overwhelming to consider.
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